The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a rare type of ovarian ...

US FDA approves Verastem’s Avmapki Fakzynja combo therapy to treat patients with KRAS-mutated recurrent low-grade serous ovarian cancer: Boston Saturday, May 10, 2025, 13:00 Hrs ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Verastem Oncology’s oral combination therapy ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...

The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...

Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...

The FDA has granted accelerated approval to Avmapki (avutometinib) plus Fakzynja (defactinib) for the treatment of KRAS-mutated, recurrent low-grade serous ovarian cancer.

The Food and Drug Administration on Thursday granted accelerated approval to Verastem Inc.’s (NASDAQ ... KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic ...

FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for ...

The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a type of ovarian cancer ...

May 8 (Reuters) - The U.S. Food and Drug Administration has approved Verastem's (VSTM.O), opens new tab combination therapy for patients with a rare type of ovarian cancer who have received prior ...

Matthew Herper joins Adam and Allison to examine Prasad’s appointment and the band of outsiders now in charge of U.S. health ...